Manuscripts and Publications

Filters: First Letter Of Last Name is K  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
H
Kim-Chang JJ, Donovan K, Loop MShane, Hong S, Fischer B, Venturi G, Garvie PA, Kohn J, H Rendina J, Woods SP et al..  2019.  Higher soluble CD14 levels are associated with lower visuospatial memory performance in Youth with HIV (YWH).. AIDS.
Kim-Chang JJ, Donovan K, Loop MShane, Hong S, Fischer B, Venturi G, Garvie PA, Kohn J, H Rendina J, Woods SP et al..  2019.  Higher soluble CD14 levels are associated with lower visuospatial memory performance in Youth with HIV (YWH).. AIDS.
Mullins TLKowalczy, Zimet G, Lally M, Xu J, Thornton S, Kahn JA.  2017.  HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults.. AIDS Patient Care STDS. 31(12):504-516.
Lally MA, van den Berg JJ, Westfall AO, Rudy BJ, Hosek SG, J Fortenberry D, Monte D, Tanney MR, McFarland EJ, Xu J et al..  2018.  HIV Continuum of Care for Youth in the United States.. J Acquir Immune Defic Syndr. 77(1):110-117.
Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G et al..  2017.  An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.. J Acquir Immune Defic Syndr. 74(1):21-29.
Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G et al..  2017.  An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.. J Acquir Immune Defic Syndr. 74(1):21-29.
Philbin MM, Tanner AE, Duval A, Ellen JM, Xu J, Kapogiannis B, Bethel J, J Fortenberry D.  2016.  HIV Testing, Care Referral, and Linkage to Care Intervals Affect Time to Engagement in Care for Newly Diagnosed HIV-Infected Adolescents in 15 Adolescent Medicine Clinics in the United States.. J Acquir Immune Defic Syndr. 72(2):222-9.
Ellen JM, Kapogiannis B, J Fortenberry D, Xu J, Willard N, Duval A, Pace J, Loeb J, Monte D, Bethel J.  2014.  HIV viral load levels and CD4+ cell counts of youth in 14 cities.. AIDS. 28(8):1213-9.
Kahn JA, Lee J, Belzer M, Palefsky JM.  2018.  HIV-Infected Young Men Demonstrate Appropriate Risk Perceptions and Beliefs about Safer Sexual Behaviors after Human Papillomavirus Vaccination.. AIDS Behav. 22(6):1826-1834.
I
Barnes W, D'Angelo L, Yamazaki M, Belzer M, Schroeder S, Palmer-Castor J, Futterman D, Kapogiannis B, Muenz L, D Harris R et al..  2010.  Identification of HIV-infected 12- to 24-year-old men and women in 15 US cities through venue-based testing.. Arch Pediatr Adolesc Med. 164(3):273-6.
Rudy BJ, Kapogiannis BG, Worrell C, Squires K, Bethel J, Li S, Wilson CM, Agwu A, Emmanuel P, Price G et al..  2015.  Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.. J Acquir Immune Defic Syndr. 69(1):52-60.
Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, Wilson CM, Worrell C, Squires KE.  2013.  Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.. Clin Infect Dis. 57(5):735-44.
Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, Wilson CM, Worrell C, Squires KE.  2013.  Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.. Clin Infect Dis. 57(5):735-44.
Bansal A, Yue L, Conway J, Yusim K, Tang J, Kappes J, Kaslow RA, Wilson CM, Goepfert PA.  2007.  Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents.. AIDS. 21(18):2387-97.
Bansal A, Yue L, Conway J, Yusim K, Tang J, Kappes J, Kaslow RA, Wilson CM, Goepfert PA.  2007.  Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents.. AIDS. 21(18):2387-97.
Mehta N, Cunningham CK, Flynn P, Pepe J, Obaro S, Kapogiannis BG, Bethel J, Luzuriaga K.  2010.  Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination.. Vaccine. 28(21):3672-8.
J Fortenberry D, Koenig LJ, Kapogiannis BG, Jeffries CL, Ellen JM, Wilson CM.  2017.  Implementation of an Integrated Approach to the National HIV/AIDS Strategy for Improving Human Immunodeficiency Virus Care for Youths.. JAMA Pediatr. 171(7):687-693.
J Fortenberry D, Koenig LJ, Kapogiannis BG, Jeffries CL, Ellen JM, Wilson CM.  2017.  Implementation of an Integrated Approach to the National HIV/AIDS Strategy for Improving Human Immunodeficiency Virus Care for Youths.. JAMA Pediatr. 171(7):687-693.
Lee S, Kapogiannis BG, Allison S.  2019.  Improving the Youth HIV Prevention and Care Continuums: The Adolescent Medicine Trials Network for HIV/AIDS Interventions.. JMIR Res Protoc. 8(3):e12050.
Mullins TLK, Rudy BJ, Wilson CM, Sucharew H, Kahn JA.  2013.  Incidence of sexually transmitted infections in HIV-infected and HIV-uninfected adolescents in the USA.. Int J STD AIDS. 24(2):123-7.
Hosek SG, Green KR, Siberry G, Lally M, Balthazar C, Serrano PA, Kapogiannis B.  2013.  Integrating Behavioral HIV Interventions into Biomedical Prevention Trials with Youth: Lessons from Chicago's Project PrEPare.. J HIV AIDS Soc Serv. 12(3-4)
Brick LAnn D, Nugent NR, Kahana SY, Bruce D, Tanney MR, M Fernández I, Bauermeister JA.  2018.  Interaction Effects of Neighborhood Disadvantage and Individual Social Support on Frequency of Alcohol Use in Youth Living with HIV.. Am J Community Psychol. 61(3-4):276-284.
M
Knopf AS, Ott MA, Liu N, Kapogiannis BG, Zimet GD, J Fortenberry D, Hosek SG.  2017.  Minors' and Young Adults' Experiences of the Research Consent Process in a Phase II Safety Study of Pre-exposure Prophylaxis for HIV.. J Adolesc Health. 61(6):747-754.
Knopf AS, Ott MA, Liu N, Kapogiannis BG, Zimet GD, J Fortenberry D, Hosek SG.  2017.  Minors' and Young Adults' Experiences of the Research Consent Process in a Phase II Safety Study of Pre-exposure Prophylaxis for HIV.. J Adolesc Health. 61(6):747-754.
Knopf AS, Gilbert ALewis, Zimet GD, Kapogiannis BG, Hosek SG, J Fortenberry D, Ott MA.  2017.  Moral conflict and competing duties in the initiation of a biomedical HIV prevention trial with minor adolescents.. AJOB Empir Bioeth. 8(3):145-152.
Knopf AS, Gilbert ALewis, Zimet GD, Kapogiannis BG, Hosek SG, J Fortenberry D, Ott MA.  2017.  Moral conflict and competing duties in the initiation of a biomedical HIV prevention trial with minor adolescents.. AJOB Empir Bioeth. 8(3):145-152.
Giguere R, Zimet GD, Kahn JA, Dolezal C, Leu C-S, Mabragaña M, McGowan I, Carballo-Diéguez A.  2013.  The Motivations and Experiences of Young Women in a Microbicide Trial in the USA and Puerto Rico.. World J AIDS. 3(3)
Naar-King S, Parsons JT, Murphy D, Kolmodin K, D Harris R.  2010.  A multisite randomized trial of a motivational intervention targeting multiple risks in youth living with HIV: initial effects on motivation, self-efficacy, and depression.. J Adolesc Health. 46(5):422-8.
Yu XG, Lichterfeld M, Chetty S, Williams KL, Mui SK, Miura T, Frahm N, Feeney ME, Tang Y, Pereyra F et al..  2007.  Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with a two-amino-acid difference between HLA class I subtypes.. J Virol. 81(4):1619-31.
Yu XG, Lichterfeld M, Chetty S, Williams KL, Mui SK, Miura T, Frahm N, Feeney ME, Tang Y, Pereyra F et al..  2007.  Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with a two-amino-acid difference between HLA class I subtypes.. J Virol. 81(4):1619-31.
P
Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR et al..  2008.  Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.. Antimicrob Agents Chemother. 52(2):631-7.
Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR et al..  2008.  Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.. Antimicrob Agents Chemother. 52(2):631-7.
Baheti G, Kiser JJ, Havens PL, Fletcher CV.  2011.  Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.. Antimicrob Agents Chemother. 55(11):5294-9.
Biello KB, Psaros C, Krakower DS, Marrow E, Safren SA, Mimiaga MJ, Hightow-Weidman L, Sullivan P, Mayer KH.  2019.  A Pre-Exposure Prophylaxis Adherence Intervention (LifeSteps) for Young Men Who Have Sex With Men: Protocol for a Pilot Randomized Controlled Trial.. JMIR Res Protoc. 8(1):e10661.
Sales JM, Escoffery C, Hussen SA, Haddad LB, Phillips A, Filipowicz T, Sanchez M, McCumber M, Rupp B, Kwiatkowski E et al..  2019.  Pre-Exposure Prophylaxis Integration into Family Planning Services at Title X Clinics in the Southeastern United States: A Geographically-Targeted Mixed Methods Study (Phase 1 ATN 155).. JMIR Res Protoc. 8(6):e12774.
Kahn JA, Belzer M, Chi X, Lee J, Gaur AH, Mayer K, Martinez J, Futterman DC, Stier EA, Paul ME et al..  2019.  Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men.. Papillomavirus Res. 7:52-61.
Gamarel KE, Brown L, Kahler CW, M Fernández I, Bruce D, Nichols S.  2016.  Prevalence and correlates of substance use among youth living with HIV in clinical settings.. Drug Alcohol Depend. 169:11-18.
Kahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, Gonin R, Liu N, Worrell C, Wilson CM.  2012.  Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.. J Acquir Immune Defic Syndr. 61(3):390-9.
Kahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, Gonin R, Liu N, Worrell C, Wilson CM.  2012.  Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.. J Acquir Immune Defic Syndr. 61(3):390-9.
Kahn JA, Rudy BJ, Xu J, Kapogiannis B, Secord E, Gillison M.  2016.  Prevalence and risk factors for oral DNA tumor viruses in HIV-infected youth.. J Med Virol. 88(11):1944-52.
Kahn JA, Rudy BJ, Xu J, Kapogiannis B, Secord E, Gillison M.  2016.  Prevalence and risk factors for oral DNA tumor viruses in HIV-infected youth.. J Med Virol. 88(11):1944-52.
Kapogiannis BG, Leister E, Siberry GK, Van Dyke RB, Rudy B, Flynn P, Williams PL.  2016.  Prevalence of and progression to abnormal noninvasive markers of liver disease (aspartate aminotransferase-to-platelet ratio index and Fibrosis-4) among US HIV-infected youth.. AIDS. 30(6):889-98.
Viani RM, Peralta L, Aldrovandi G, Kapogiannis BG, Mitchell R, Spector SA, Lie YS, Weidler JM, Bates MP, Liu N et al..  2006.  Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study.. J Infect Dis. 194(11):1505-9.

Pages